SUPERNUS PHARMACEUTICALS INC (SUPN)

US8684591089 - Common Stock

35.43  -0.34 (-0.95%)

After market: 35.43 0 (0%)

News Image
a month ago - Supernus Pharmaceuticals, Inc.

Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference

ROCKVILLE, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and...

News Image
a month ago - Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference

ROCKVILLE, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and...

News Image
2 months ago - Supernus Pharmaceuticals, Inc.

Supernus Announces Third Quarter 2024 Financial Results

News Image
2 months ago - Supernus Pharmaceuticals, Inc.

Supernus Announces Third Quarter 2024 Financial Results

Net sales of Qelbree® increased 68% in the third quarter of 2024, compared to the same period in 2023. Net sales of Qelbree of $62.4 million and $166.9...

News Image
2 months ago - Supernus Pharmaceuticals, Inc.

Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024

Participants in the Phase 2a study experienced rapid and meaningful decreases in depressive symptoms Suicidal ideation decreased by 80% SPN-820 was...

News Image
2 months ago - Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results

ROCKVILLE, Md., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and...

News Image
2 months ago - Supernus Pharmaceuticals, Inc.

Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder

Phase 2a study demonstrated rapid and substantial decrease in depressive symptoms SPN-820 was well-tolerated with few adverse events SPN-820 is a novel,...

News Image
2 months ago - Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder

ROCKVILLE, Md., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and...

News Image
3 months ago - Supernus Pharmaceuticals, Inc.

Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree

Ahead of ADHD Awareness Month, Busy is sharing her ADHD diagnosis and Qelbree® (viloxazine extended-release capsules) treatment story to empower women...

News Image
3 months ago - Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit

ROCKVILLE, Md., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and...

News Image
4 months ago - Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference

ROCKVILLE, Md., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and...

News Image
4 months ago - Supernus Pharmaceuticals, Inc.

Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA

PDUFA Target Action Date of February 1, 2025 ROCKVILLE, Md., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a...

News Image
5 months ago - Supernus Pharmaceuticals, Inc.

Supernus Announces Second Quarter 2024 Financial Results

News Image
5 months ago - Supernus Pharmaceuticals, Inc.

Supernus Announces Second Quarter 2024 Financial Results

Net sales of Qelbree® increased 92% in the second quarter of 2024, compared to the same period in 2023. $59.4 million and $104.5 million of net sales in...

News Image
5 months ago - Supernus Pharmaceuticals, Inc.

Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device

News Image
5 months ago - Supernus Pharmaceuticals, Inc.

Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device

ROCKVILLE, Md., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and...

News Image
5 months ago - Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024

ROCKVILLE, Md., July 23, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and...

News Image
5 months ago - InvestorPlace

If You Can Only Buy One Biotech Stock in July, It Better Be One of These 3 Names

Evaluating and making money from biotech stocks is incredibly difficult. These three ideas should help your quest if buying in July.

News Image
7 months ago - Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

ROCKVILLE, Md., May 30, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and...